Does CVS Caremark Cover Weight-Loss Drugs? (2026)

Short version: CVS Caremark is a pharmacy-benefit manager (PBM), not an insurer. It does not decide whether you have coverage — it publishes the formulary, sets prior-authorization rules, and adjudicates claims for the health plans and employers (plan sponsors) that hire it. Your plan sponsor decides whether anti-obesity medications are a covered benefit class at all. Within that, GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza) are generally covered with prior authorization. GLP-1s for chronic weight management (Wegovy, Zepbound, Saxenda) are covered only when the plan sponsor elected anti-obesity-medication (AOM) coverage. And the single biggest event: effective July 1, 2025 CVS Caremark removed Zepbound from its standard commercial formularies and made Wegovy the preferred weight-loss GLP-1 after a Novo Nordisk rebate deal. After patient backlash and a class-action lawsuit, Caremark is restoring Zepbound as a co-preferred option effective October 1, 2026.^[1][7]

At a glance

• CVS Caremark is a PBM, not an insurer. It is the largest of the three big pharmacy-benefit managers. It publishes formularies, sets PA and step-therapy rules, and adjudicates pharmacy claims for the health plans and employers that hire it. The decision to have weight-loss coverage belongs to the plan sponsor; Caremark administers it.^[1][2]
• Type 2 diabetes GLP-1s: generally covered with prior authorization. Ozempic, Mounjaro, Trulicity, Rybelsus, and Victoza appear on most Caremark commercial formularies for the T2D indication.^[2]
• Chronic-weight-management GLP-1s: covered only if the plan sponsor elected the AOM benefit. Wegovy, Zepbound, and Saxenda are covered when anti-obesity medications are included and excluded when the employer carved them out. This is the single biggest determinant of coverage.^[2]
• The 2025 switch: effective July 1, 2025, CVS Caremark removed Zepbound from its Standard, Advanced Control, and Value commercial formularies and made Wegovy the single preferred weight-loss GLP-1 after a rebate agreement with Novo Nordisk. Caremark was the only major PBM to exclude Zepbound while keeping Wegovy.^[3][7]
• The 2026 reversal: after patient backlash and a September 2025 class-action lawsuit arguing the two drugs are not medically interchangeable, CVS Caremark is restoring Zepbound as an additional (co-preferred) option on the standard commercial formulary template effective October 1, 2026, with the same copay as Wegovy. Separately, it added the oral GLP-1 Foundayo (orforglipron) effective June 1, 2026.^[1][6][7]
• Medicare Part D: NO for weight-loss-only Wegovy/Zepbound/Saxenda — federal law (Social Security Act §1860D-2(e)(2)(A), codified from the Medicare Modernization Act of 2003) excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain.” YES for Ozempic/Mounjaro for diabetes and (formulary-dependent) Wegovy for cardiovascular risk reduction.^[8][9]
• Typical PA pattern (Wegovy/Zepbound): BMI ≥ 30, OR BMI ≥ 27 with a weight-related comorbidity, age 18+, and documented participation in a comprehensive weight-management program for at least 6 months; continuation conditioned on documented weight loss (commonly ≥5% of baseline).^[4]

What CVS Caremark actually is (and is not)

CVS Caremark is a pharmacy-benefit manager — a middleman between drug makers, pharmacies, and the health plans or employers that pay for prescriptions. It is the largest of the three big PBMs (alongside Express Scripts and OptumRx), and it is the pharmacy-benefit arm of CVS Health, the same parent company that owns the Aetna insurer and CVS retail pharmacies.^[1][2]

The distinction matters enormously for the question “does CVS Caremark cover weight-loss drugs.” A PBM does not, strictly speaking, cover anything. It performs three jobs for whoever hires it:

1. Builds the formulary. Caremark negotiates rebates with manufacturers and decides which drugs are preferred, non-preferred, or excluded on each template formulary (Standard, Advanced Control, Value, and others). When Caremark changes its preferred weight-loss GLP-1, every plan on that template inherits the change.^[7]
2. Sets and adjudicates utilization management. Prior authorization, step therapy, and quantity limits are written and processed by Caremark. PA requests route through the CVS Caremark prescriber portal or fax.^[4]
3. Processes pharmacy claims. When you fill a prescription, the pharmacy bills Caremark, which applies your plan's copay/tier and pays the pharmacy.

What Caremark does not do is decide whether your benefit includes anti-obesity medications at all. That is the plan sponsor's decision — your employer (for self-funded plans, which are a large share of the commercial market), or the health plan that contracts with Caremark. As CVS itself puts it, “plan sponsors that adopt CVS Caremark template formularies retain discretion to customize coverage for their members.”^[1] Two people with prescriptions run through CVS Caremark can have completely different weight-loss-drug coverage.

GLP-1 coverage for type 2 diabetes (widely covered)

For the type 2 diabetes indication, GLP-1 receptor agonists are generally on-formulary on Caremark commercial plans with prior authorization. Because T2D is not a weight-loss indication, these agents sit on the diabetes side of the formulary and are not affected by the AOM-rider question. Commonly covered:

• Ozempic (semaglutide) — once-weekly injection, FDA-approved for T2D + cardiovascular risk reduction in T2D with established CVD. See our semaglutide drug page.
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1, FDA-approved for T2D. See our tirzepatide drug page.
• Trulicity (dulaglutide) — once-weekly GLP-1, FDA-approved for T2D + CV risk reduction.
• Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D.
• Victoza (liraglutide) — daily GLP-1, FDA-approved for T2D; older agent with branded and authorized-generic forms.

Typical Caremark PA criteria for a T2D GLP-1: a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C, usually a trial of metformin (or documented intolerance/contraindication), and prescriber documentation of treatment goals.^[2]

GLP-1 coverage for chronic weight management (plan-sponsor benefit)

This is where coverage becomes conditional. The FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg; indication: chronic weight management in adults and pediatric patients aged 12+ with obesity, plus cardiovascular risk reduction, per DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b^[5]), Zepbound (tirzepatide; indication: chronic weight management plus moderate-to-severe obstructive sleep apnea in adults with obesity, per DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b^[10]), and Saxenda (liraglutide 3.0 mg) — are covered only when the plan sponsor includes the anti-obesity-medication benefit.

AOM coverage is not a standard inclusion. It is effectively a benefit the plan sponsor elects to buy. Many employers carve anti-obesity medications out of the prescription benefit entirely to control premium cost — and when they do, no amount of medical-necessity documentation will produce coverage, because the benefit class itself is excluded.^[2]

When the plan does include AOMs, the published Caremark/plan PA criteria for Wegovy and Zepbound are well-defined:^[4]

• BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or — for the Zepbound OSA pathway — moderate-to-severe obstructive sleep apnea).
• Age 18 or older for the weight-management indication (12+ for the Wegovy pediatric obesity indication).
• Documented participation in a comprehensive weight-management program — behavioral modification, reduced-calorie diet, and increased physical activity with follow-up — for at least 6 months prior to or alongside the request.
• Continuation conditioned on documented weight loss, commonly at least 5% of baseline. Quantity limits apply (typically 1 carton/month by dose strength).

For the underlying weight-loss magnitudes that anchor these PA decisions, see our best semaglutide providers ranking.

The 2025 Zepbound exclusion and the 2026 reversal

The most consequential change to weight-loss coverage on Caremark-administered plans in years came from the PBM's formulary strategy, not from any insurer's medical side. Effective July 1, 2025, CVS Caremark removed Zepbound (tirzepatide) from its Standard, Advanced Control, and Value commercial formularies — the templates most employers use — and designated Wegovy (semaglutide 2.4 mg) as the single preferred anti-obesity GLP-1, following a rebate agreement with Novo Nordisk. Caremark was the only one of the three major PBMs to exclude Zepbound while keeping Wegovy covered.^[3][7]

For members on plans following the standard template that included AOM coverage, the practical effect was: Wegovy was the covered weight-loss GLP-1 and Zepbound was no longer covered for weight loss as of July 1, 2025. Existing Zepbound prior authorizations were generally transferred to Wegovy (keeping the original expiration date), and members who could not tolerate or did not respond to Wegovy had to pursue a formulary exception.^[3]

The switch drew significant patient backlash. In September 2025, patients filed a class-action lawsuit contending that Zepbound and Wegovy are not medically interchangeable — citing that some patients who lost weight on Zepbound regained it after being forced to switch to Wegovy.^[7] In response, CVS Caremark announced a partial reversal: Zepbound returns as an additional preferred (co-preferred) option on the standard commercial formulary template effective October 1, 2026, putting Wegovy and Zepbound side-by-side with the same copay. The change affects roughly 25 to 30 million Americans on Caremark's standard commercial template. Separately, Caremark added the new oral GLP-1 Foundayo (orforglipron) effective June 1, 2026.^[1][6][7]

CVS Caremark and Medicare Part D — the federal exclusion

CVS Caremark also administers prescription benefits for many Medicare Part D and Medicare Advantage plans (including those run by sister company Aetna). Like every Part D plan, those plans operate under Social Security Act §1860D-2(e)(2)(A) — codified from the Medicare Modernization Act of 2003 — which explicitly excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain” from Part D coverage.^[8] This is a federal statutory exclusion: no Caremark-administered Part D plan can cover Wegovy, Zepbound, or Saxenda for weight-loss-only indications, regardless of medical-necessity documentation.

Two indication-specific carve-ins exist where a Part D plan CAN cover an otherwise-excluded GLP-1:

• Ozempic / Mounjaro / Trulicity for type 2 diabetes. T2D is not a weight-loss indication, so the §1860D-2(e)(2)(A) exclusion does not apply.^[9]
• Wegovy for cardiovascular risk reduction. After the FDA's March 2024 approval of Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight/obesity, CMS confirmed Part D plans may add Wegovy to their formularies for that non-weight-loss indication. KFF estimated roughly 3.6 million Medicare beneficiaries could qualify under this pathway. Individual plan formularies vary on how aggressively they cover it.^[5][9]

The Zepbound obstructive-sleep-apnea indication (FDA-approved December 20, 2024) is likewise a non-weight-loss indication, so a Part D plan can cover Zepbound for moderate-to-severe OSA in adults with obesity subject to prior authorization.^[10]

How to find out if YOUR plan covers Wegovy or Zepbound

Four reliable ways, in order from fastest to most authoritative:

1. CVS Caremark member portal → drug-cost / formulary lookup. Sign in to caremark.com (or the Caremark mobile app), search “Wegovy” or “Zepbound,” and the result shows the tier, the PA requirement, and — critically — whether the AOM benefit applies to your specific plan. The signed-in lookup reflects your plan and group, not the generic template.^[1]
2. Phone the number on your CVS Caremark card. Ask specifically: “Does my plan include anti-obesity-medication coverage? Is (drug name) covered for chronic weight management, what tier, and what is the PA requirement?” The AOM-benefit question is the one that matters most.
3. Ask your HR or benefits administrator about the AOM benefit. For employer-sponsored plans, HR knows whether the plan bought anti-obesity-medication coverage and whether it follows the standard Caremark template or a custom one. This is often faster than the portal for the benefit-class question.
4. Request the Summary of Benefits and Coverage (SBC) and the prescription-drug rider. The SBC and drug rider state whether AOMs are an excluded benefit class. If they are excluded, that is dispositive.

Prior authorization and step therapy at CVS Caremark

Because Caremark is the PBM, prior authorization runs entirely through it:

1. Your prescriber evaluates you against the published PA criteria — BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity), age 18+, plus the documented comprehensive weight-management program for Wegovy/Zepbound.^[4]
2. If criteria are met, the prescriber submits the PA through the CVS Caremark prescriber portal (electronic PA) or by fax to Caremark.
3. Step therapy / preferred-agent rules apply. On standard templates from July 1, 2025, Wegovy was the required preferred weight-loss GLP-1; from October 1, 2026 both Wegovy and Zepbound are co-preferred on the standard template, so step therapy between the two largely falls away on plans that adopt it.^[7]
4. CVS Caremark adjudicates the PA. Standard turnaround is typically within a few business days for non-urgent requests; expedited review is available for urgent cases. If approved, you fill at a participating retail or mail-order pharmacy and the plan copay/tier applies; continuation requires documented weight loss (commonly ≥5% of baseline).^[4]

If denied or excluded — what actually works

Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:

• Request a formulary exception (the Wegovy/Zepbound switch case). If your plan covers one preferred weight-loss GLP-1 and you cannot tolerate it or it did not work, your prescriber can request a formulary exception for the non-preferred agent with documentation. This was the most common path for members caught in the 2025 Zepbound exclusion, and Caremark opened an exception process specifically for it.^[3]
• Internal appeal, then external review. Commercial members can appeal a denial in writing (commonly within 180 days), then escalate to an Independent Review Organization. Key distinction: if AOMs are a carved-out benefit class, that is a plan-design exclusion, not a medical-necessity denial, and is generally not appealable on clinical grounds.
• The Zepbound OSA or Wegovy CV-risk pathway. If you have moderate-to-severe OSA (Zepbound) or established CVD plus overweight/obesity (Wegovy), your prescriber can submit a PA for the non-weight-loss indication — coverable even on Medicare Part D.^[5][10]
• Manufacturer copay cards. Eligible commercial members can pay as little as $25/month for Wegovy or Zepbound through Novo Nordisk and Eli Lilly savings programs when the drug is covered.^[7]
• LillyDirect Self Pay vials (roughly $299-$699/month) or compounded 503A telehealth tirzepatide/semaglutide (typically $149-$349/month; not brand Wegovy/Zepbound). Cash-pay; no PBM involvement.
• Compare other payers and PBMs. See how the integrated insurer that shares CVS Caremark handles the same drugs in our Aetna weight-loss-drug coverage review, how a rival PBM-backed insurer compares in our Cigna review, and how an integrated HMO differs in our Kaiser Permanente review.

Verdict — what CVS Caremark members should expect

For anyone asking does CVS Caremark cover weight-loss drugs, the answer splits by who actually decides and by indication:

1. CVS Caremark is a PBM, not an insurer. It administers — it does not own — your coverage. Your plan sponsor decides whether anti-obesity medications are a covered benefit class.
2. T2D GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza): generally YES with prior authorization confirming the diabetes diagnosis.
3. Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda): only if your plan sponsor elected the AOM benefit. From July 1, 2025 the standard formulary preferred Wegovy and excluded Zepbound; from October 1, 2026 Zepbound returns as co-preferred — but only on plans that adopt the standard template.
4. Medicare Part D (Caremark-administered plans): NO for weight-loss-only; YES for diabetes GLP-1s, Wegovy CV-risk reduction, and Zepbound OSA.

The PBM model means the formulary is a moving target driven by rebate negotiations — the 2025 Zepbound exclusion and 2026 co-preferred reversal are the clearest recent example. The single most important question is not “is the drug on the Caremark formulary” but “did my plan sponsor include the anti-obesity-medication benefit at all, and does my plan follow the standard template.” For provider options once you confirm coverage, see our best semaglutide providers ranking.

Further reading

• Does Aetna cover weight-loss drugs? (Aetna's pharmacy benefit is run by CVS Caremark)
• Does Cigna cover weight-loss drugs?
• Does Kaiser Permanente cover weight-loss drugs?